Effectiveness of low-dose intramuscular Anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report

Alonso, Isabel; Tejada, Alberto Herreros de; Moreno, José María Ruiz; Rubio, Elena Múñez; Lucena, Juan J.; Revilla, Juan de la; Turrión, Víctor Sánchez; Gomez, Ana; López, José María Rodríguez; Cuervas-Mons, Valentín

doi:10.1016/s0041-1345(03)00634-1

Cited by 16 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HBV DNA should be monitored at least 3-monthly. Neg., negative; pos., positive; HCC, hepatocellular carcinoma Hepatitis B and liver transplantation Hepatitis B and liver transplantation 11 11 Subsequent dosing that is based on a fixed dose HBIG regimen has been endorsed in some transplant centres since the early 1990s [59][60][61][62]. Others have individualised HBIG administration according to anti-hepatitis B surface (anti-HBs) titer, commonly targeting maintenance of trough levels at greater than 100 IU/L (Table 4) [55][56][57][63][64][65][66][67][68].…”

Section: Prophylaxis Of Hepatitis B Recurrence After Liver Transplantmentioning

confidence: 99%

Hepatitis B and liver transplantation: 2008 update

Beckebaum

Sotiropoulos

Gerken

et al. 2008

Reviews in Medical Virology

View full text Add to dashboard Cite

The ultimate goal of treatment is suppression of viral replication to undetectable HBV-DNA levels prior to and after liver transplantation (LT) to prevent infection of the newly transplanted liver. Most published data are available from therapy with lamivudine (LAM) in pre- and post-transplant HBV patients. Add-on therapy with adefovir dipivoxil (ADV) in pre-transplant LAM-resistant patients has been shown to represent an effective antiviral strategy leading to hepatic recompensation in many cases and, eventually, removal from the waiting list. Newer nucleos(t)ide analogues such as entecavir, tenofovir and telbivudine have shown lower resistance rates than LAM and more antiviral potency in studies in the non-transplant setting. Combined hepatitis B immune globulin (HBIG) and nucleos(t)ide analogue therapy have been widely adopted as the most effective treatment strategy against recurrent HBV disease after LT. Many programs have evaluated lower doses or a shorter duration of HBIG and intramuscular versus intravenous routes of administration. Active immunisation using recombinant HBV vaccines, including the S, pre-S1 and pre-S2 regions, and those with immunostimulatory adjuvants, seem to be more immunogenic than the currently available vaccines and have been used in studies to replace HBIG. Furthermore, it has been shown that immune memory against HBV can be adoptively transferred from organ donors to transplant recipients. Nucleos(t)ide analogue combination therapies might provide an alternative to the current treatment paradigm with costly HBIG; however, experience with this new treatment regimen is very limited and controlled clinical studies are urgently warranted to investigate its safety and efficacy and to determine which nucleos(t)ide analogue combinations will be the most promising in the long term after LT.

show abstract

Section: Prophylaxis Of Hepatitis B Recurrence After Liver Transplantmentioning

confidence: 99%

Hepatitis B and liver transplantation: 2008 update

Beckebaum

Sotiropoulos

Gerken

et al. 2008

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…En otros estudios se han utilizado dosis entre 10.000 y 5.000 UI endovenosa por día durante la primera semana, seguidas de 5.000 UI endovenosa tres veces a la semana en la segunda semana y luego 5.000 UI mensuales en forma indefinida 12,13 . También se ha reportado en una serie pequeña el uso de HBIg intramuscular desde la fase anhepática del trasplante (2.000 UI en ese momento, seguido de la administración de 2.000 UI diarias por siete días y posteriormente 2.000 UI mensuales en forma indefinida) logrando mantener HBsAg negativo al año de seguimiento 14 .Otros estudios más recientes utilizan entre 400 a 800 UI vía IM en forma mensual asociado a Lamivudina con resultados bastante promisorios 15 . La recurrencia de la infección por el VHB con el uso de HBIg en dosis altas, como terapia única, varía entre 7 y 23% con seguimientos entre 2 y 55 meses.…”

Section: Discussionunclassified

Trasplante hepático en cirrosis por virus B: profilaxis con gammaglobulina antiHBs en dosis a "demanda"

et al. 2012

View full text Add to dashboard Cite

“…Angus/2008 [32] Avolio/2008 [106] Angus/2000 [51] Anselmo/2002 [33] Anderson/2007 [107] Alonso/2003 [108] Brock/2011 [109] Buti/2003 [110] Ben-Ari/2004 [111] Chun/2010 [112] Dadson/2000 [113] Dehghani/2013 [114] Dickson/2006 [59] Dumortier/2003 [115] Degertekin/2010 [116] Di Paolo/2004 [117] Faust/2003 [118] Freshwater/2008 [99] Fabrega/2003 [119] Feretti/2004 [120] Filipponi/2010 [121] Gane/2013 [55] Han/2000 [35] Han/2003 [122] Honaker/2002 [123] Iacob/2008 [124] Jiang/2010 [125] Jain/2005 [126] Jiao/2007 [127] Karademir/2006 [128] Kwon/2006 [129] Lee/2000 [130] Lee/2004 [131] Lu/2004 [85] Lu/2008 [39] Loss/2003 [132]…”

Section: Authormentioning

confidence: 99%